Vasodilator Therapy for Heart Failure and Preserved Ejection Fraction
Status:
Completed
Trial end date:
2018-03-01
Target enrollment:
Participant gender:
Summary
The main objective is to test the effect of prolonged therapy (24 weeks) with isosorbide
dinitrate ± hydralazine on arterial wave reflections (primary endpoint). Secondary endpoints
include left ventricular (LV) mass, fibrosis and diastolic function) and exercise capacity
(assessed via the 6-minute walk test) in patients with Heart Failure and Preserved Ejection
Fraction (HFPEF). We will also test the hypothesis that the reduction in arterial wave
reflections induced by vasoactive therapy will correlate with the improvement in exercise
capacity, LV mass, fibrosis and diastolic function. Finally, we will assess whether the
hemodynamic response to an acute dose of sublingual nitroglycerin (NTG) can predict the
sustained changes in the reflected wave and other hemodynamic parameters in response to
chronic vasodilator therapy.
Phase:
Phase 2
Details
Lead Sponsor:
Corporal Michael J. Crescenz VA Medical Center
Collaborators:
National Institute on Aging (NIA) University of Pennsylvania